RT Journal Article
T1 Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study.
A1 Ibáñez-Sanz, Gemma
A1 Díez-Villanueva, Anna
A1 Vilorio-Marqués, Laura
A1 Gracia, Esther
A1 Aragonés, Nuria
A1 Olmedo-Requena, Rocío
A1 Llorca, Javier
A1 Vidán, Juana
A1 Amiano, Pilar
A1 Nos, Pilar
A1 Fernández-Tardón, Guillermo
A1 Rada, Ricardo
A1 Chirlaque, María Dolores
A1 Guinó, Elisabet
A1 Dávila-Batista, Verónica
A1 Castaño-Vinyals, Gemma
A1 Pérez-Gómez, Beatriz
A1 Mirón-Pozo, Benito
A1 Dierssen-Sotos, Trinidad
A1 Etxeberria, Jaione
A1 Molinuevo, Amaia
A1 Álvarez-Cuenllas, Begoña
A1 Kogevinas, Manolis
A1 Pollán, Marina
A1 Moreno, Victor
AB A safe and effective colorectal cancer (CRC) chemoprevention agent remains to be discovered. We aim to evaluate the association between the use of glucosamine and/or chondroitin sulphate and risk of colorectal cancer (CRC) in the MCC-Spain study, a case-control study performed in Spain that included 2140 cases of CRC and 3950 population controls. Subjects were interviewed on sociodemographic factors, lifestyle, family and medical history and regular drug use. Adjusted odds ratios and their 95% confidence intervals were estimated. The reported frequency of chondroitin and/or glucosamine use was 2.03% in controls and 0.89% in cases. Users had a reduced risk of CRC (OR: 0.47; 95% CI: 0.28-0.79), but it was no longer significant when adjusted for NSAID (nonsteroidal anti-inflammatory drugs) use (OR: 0.82; 95% CI: 0.47-1.40). A meta-analysis with previous studies suggested a protective effect, overall and stratified by NSAID use (OR: 0.77; 95% CI: 0.62-0.97). We have not found strong evidence of an independent preventive effect of CG on CRC in our population because the observed effects of our study could be attributed to NSAIDs concurrent use. These results merit further research due to the safety profile of these drugs.
YR 2018
FD 2018-02-01
LK http://hdl.handle.net/10668/12077
UL http://hdl.handle.net/10668/12077
LA en
DS RISalud
RD Apr 6, 2025